← back to search

Flavio Solca

Boehringer Ingelheim (India) · AT
🔎 Find collaborators in Pulmonary and Respiratory Medicine · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Microtubule and mitosis dynamics, and Cancer, Hypoxia, and Metabolism.
h-index
33
citations
5,408
works
199
NIH funding
primary concept
Medicine
email

Recent publications

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
Annals of Oncology 2020cited by 167position: middledoi
Therapeutic Potential of Afatinib in<i>NRG1</i>Fusion-Driven Solid Tumors: A Case Series
The Oncologist 2020cited by 57position: middledoi
Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.
Journal of Global Oncology 2019cited by 6position: middledoi
NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option
Annals of Oncology 2019cited by 4position: middledoi
Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Annals of Oncology 2019cited by 4position: middledoi
NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib
Annals of Oncology 2019cited by 3position: middledoi
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Annals of Oncology 2017cited by 79position: middledoi
Non-reproducible sequence artifacts in FFPE tissue: an experience report
Journal of Cancer Research and Clinical Oncology 2017cited by 14position: middledoi
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
Naunyn-Schmiedeberg s Archives of Pharmacology 2014cited by 109position: lastdoi
Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Molecular Cancer Therapeutics 2012cited by 198position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Janessa Laskin · BC Cancer Agency6 papers (2019–2020)Martin Jones · The Francis Crick Institute6 papers (2019–2020)Richard F. Schlenk · Institute of Human Genetics6 papers (2019–2020)A. Cseh · Boehringer Ingelheim (Germany)6 papers (2019–2020)Christoph Heining · German Cancer Research Center6 papers (2019–2020)J. Cadranel · Université Sorbonne Nouvelle5 papers (2019–2020)Daniel J. Renouf · BC Cancer Agency5 papers (2019–2020)M. Duruisseaux · Université Claude Bernard Lyon 15 papers (2019–2020)Stephen V. Liu · Georgetown University5 papers (2019–2020)Benjamin A. Weinberg · Caris Life Sciences (United States)5 papers (2019–2020)Parneet Cheema · Université Grenoble Alpes5 papers (2019–2020)Khaled Tolba · Foundation Medicine (United States)5 papers (2019–2020)Eva Brandén · Gävle Hospital4 papers (2019–2020)Domenico Trombetta · Lund University4 papers (2019–2020)Yasushi Goto · National Cancer Centre Japan4 papers (2019–2020) · 4 papers (2019–2020)Robert C. Doebele · Institute of Biomedical Science3 papers (2019–2019)Alexander Drilon · Université Grenoble Alpes3 papers (2019–2020)Byoung Chul Cho · Université Grenoble Alpes2 papers (2012–2014)James G. Christensen · Memorial Sloan Kettering Cancer Center1 papers (2012–2012)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pulmonary and Respiratory Medicine · Oncology →